This resistance is defined as disease progression during ADT by either rising serum prostate-specific antigen (PSA) levels despite low levels of circulating testosterone (<50 ng/dl), development of symptoms in the presence of pre-existing cancer, or detecting new malignant lesions [12]. Here, KLK3 is linked to cancer.